Assessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva

Seminars in Cutaneous Medicine and Surgery

Volumn 29, Issue 1, 2010, Pages 16-19

  Seminara, Nicole M ^a   Gelfand, Joel M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

biologics; efalizumab; pharmacoepidemiology; pharmacovigilance; progressive multifocal leukoencephalopathy (PML); psoriasis

Indexed keywords

ASTEMIZOLE; EFALIZUMAB; NATALIZUMAB; PLACEBO; TERFENADINE; VALDECOXIB;

CLINICAL TRIAL; CROHN DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INFECTION; MULTIPLE SCLEROSIS; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; REVIEW; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY; TORSADE DES POINTES; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; DRUG TOXICITY; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; PSORIASIS;

EID: 77951604585     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sder.2010.01.001     Document Type: Review

References (41)

1. Gelfand J.M., Neimann A.L., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 (2006) 1735-1741
2. Gelfand J.M., Dommasch E.D., Shin D.B., et al. The risk of stroke in patients with psoriasis. J Invest Dermatol 129 (2009) 2411-2418
3. Gelfand J.M., Feldman S., Stern R., et al. Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol 51 (2004) 704-708
4. Gelfand J.M., Gladman D., Mease P., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53 (2005) 573
5. Gelfand J.M., Troxel A.B., Lewis J.D., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143 (2007) 1493-1499
6. Mehta NN, Azfar RS, Shin DB, et al: Patients with severe psoriasis are at increased risk of cardiovascular mortality: a cohort study using the general practice research database. Eur Heart J (in press)
7. Rapp S.R., Feldman S., Exum M., et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 41 3 Pt. 1 (1999) 401-407
8. Kurd S.K., and Gelfand J.M. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 60 (2009) 218-224
9. FDA (Feb 19, 2009). "FDA Public Health Advisory Updated Safety Information about Raptiva (efalizumab)". Press release. Retrieved 2009-12-05. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm110605.htm
10. Raptiva (efalizumab) [package insert] (2009), Genentech, San Francisco, CA
11. FDA (Feb 19, 2009). "FDA Advises Public of Serious Adverse Event with Psoriasis Drug Raptiva". Press release. Retrieved 2009-12-05. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149528.htm
12. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab) (2009), E.M. Agency, London, UK
13. FDA (Apr 8, 2009). "FDA Statement on the Voluntary Withdrawal of Raptiva from the U.S. Market". Press release. Retrieved 2009-12-05. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149561.htm
14. In: Strom B.L. (Ed). Pharmacoepidemiology. 4th ed. (2005), John Wiley & Sons, West Sussex, England
15. Gelfand J.M. Pharmacovigilance: verifying that drugs remain safe. In: Wolverton S.E. (Ed). Comprehensive Dermatologic Drug Therapy (2004), Elsevier, Philadelphia, PA
16. Khong T.K., and Singer D.R. Adverse drug reactions: current issues and strategies for prevention and management. Expert Opin Pharmacother 3 (2002) 1289-1300
17. Okie S. Safety in numbers-monitoring risk in approved drugs. N Engl J Med 352 (2005) 1173-1176
18. Stern R.S., Laird N., Melski J., et al. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 310 (1984) 1156-1161
19. Stern R.S., Nichols K.T., and Vakeva L.H. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 336 (1997) 1041-1045
20. Menter A., Korman N., Elmets C.A., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol 62 (2010) 114-135
21. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
22. FDA Drug Review: Postapproval risks 1976-85 (1990), FDA, Washington, DC
23. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products (2002), World Health Organization, Geneva, Switzerland
24. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
25. Stern R.S., and Chan H.L. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 21 2 Pt. 1 (1989) 317-322
26. Hazell L., and Shakir S.A. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 29 (2006) 385-396
27. Loke Y.K., Price D., Derry S., et al. Case reports of suspected adverse drug reactions-systematic literature survey of follow-up. BMJ 332 (2006) 335-339
28. Avorn J. Drug warnings that can cause fits-communicating risks in a data-poor environment. N Engl J Med 359 (2008) 991-994
29. FDA: Report on the performance of drug and biologics firms in conducting postmarketing commitment studies (2004), U.S. Department of Health & Human Services, Washington, DC
30. Schultz W.B. Bolstering the FDA's drug-safety authority. N Engl J Med 357 (2007) 2217-2219
31. Nijsten T., Spuls P., and Naldi L. The misperception that clinical trial data reflect long-term drug safety: lessons learned from efalizumab's withdrawal. Arch Dermatol 145 (2009) 1037-1039
32. Gordon K.B., Papp K.A., Hamilton T.K., et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 (2003) 3073-3080
33. Menter A., Gordon K., Carey W., et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 141 (2005) 31-38
34. Barron H. Important safety information (2008), Genentech, San Francisco, CA
35. Holman R.C., Janssen R.S., Buehler J.W., et al. Epidemiology of progressive multifocal leukoencephalopathy in the United States: analysis of national mortality and AIDS surveillance data. Neurology 41 (1991) 1733-1736
36. Korman B.D., Tyler K.L., and Korman N.J. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists. Arch Dermatol 145 (2009) 937-942
37. Major E.O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61 (2010) 35-47
38. FDA: Public health advisory-suspended marketing of Tysabri (natalizumab) (2005), U.S. Department of Health & Human Services, Washington, DC
39. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
40. DeFrancesco L. RIP Raptiva?. Nat Biotechnol 27 (2009) 303
41. Gelfand J.M. Long-term treatment for severe psoriasis: we're halfway there, with a long way to go. Arch Dermatol 143 (2007) 1191-1193